• Genfit’s NIS4-based NASHnext blood test, marketed by Labcorp under a license, secured Medicare coverage for future reimbursement in the US.
• Medicare reimbursement set at about USD 251.7 per test under the Clinical Laboratory Fee Schedule; eligibility-based payments start Aug. 10, 2026.
• Coverage is expected to accelerate adoption of the Labcorp test, positioning Genfit for recurring licensing revenue; more financial detail flagged for the fall.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief on July 02, 2026, and is solely responsible for the information contained therein.